Withdrawal Risk Assessment for Missed Medication

Critical Medication Classes with High Withdrawal Risk

The American Psychiatric Association notes that withdrawal symptoms from antidepressants typically emerge within 24-48 hours of discontinuation and include prominent physical symptoms such as dizziness, light-headedness, nausea, fatigue, sensory disturbances, and flu-like symptoms 1, 2
The Lancet Psychiatry recommends that five days without medication will likely produce significant withdrawal symptoms in patients on chronic antidepressant therapy, with symptoms being uncomfortable but not life-threatening and resolving with medication reinitiation 3, 4
The American College of Emergency Physicians states that opioid withdrawal may be very uncomfortable but is rarely directly life-threatening as a sole condition, with withdrawal symptoms developing within hours to days depending on the specific opioid's half-life 5
The Lancet Psychiatry warns that benzodiazepines and Z-drugs carry significant withdrawal risk after chronic use, with abrupt discontinuation producing serious symptoms requiring medical management 3, 4
The American Academy of Neurology notes that chronic users of gabapentinoids will experience withdrawal symptoms after 5 days of missed doses, with physical dependence requiring neuroadaptive changes that typically take longer than 3 days to develop 3, 4, 6

The Mayo Clinic recommends that carisoprodol can cause severe withdrawal symptoms and should always be tapered slowly over 4-9 days rather than stopped abruptly, while cyclobenzaprine withdrawal causes malaise, nausea, and headache for 2-4 days but symptoms are uncomfortable rather than life-threatening 7

The Lancet Psychiatry suggests that high-risk classes (antidepressants, opioids, benzodiazepines, gabapentinoids in chronic users) will produce withdrawal after 5 days, with chronic use (weeks to months) significantly increasing withdrawal risk 3, 4, 5
The American College of Physicians recommends that very short-term use (less than 5 days) has minimal risk except for specific medications like carisoprodol, and patients with concurrent psychiatric comorbidities are more likely to develop protracted withdrawal lasting months to years 1, 6, 7

The American Psychiatric Association recommends that symptomatic management has limited evidence except for medication reinitiation and slower tapering, with the most effective intervention being resuming the medication and implementing a proper taper 1, 2, 5